Associated Disease Details
| Disease ID: | I05 |
| DO ID: | 9352 |
| Disease Name: | Type 2 diabetes mellitus |
| Definition: | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 |
| Synonyms: | Diabetes Mellitus; Insulin-Dependent; Non-Insulin-Dependent; Diabetic Nephropathy; Diabetic peripheral neuropathy; hyperglycemia; hyperinsulinemia; type II diabetes mellitus; type 2 diabetes; non-insulin-dependent diabetes mellitus; NIDDM; insulin resistance; T2DM |
| Class: | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus |
| Related Drugs: | Acarbose; Alpha-lipoic acid; Canagliflozin; Dapagliflozin; Diamel; Dulaglutide; Elafibranor; Empagliflozin; Gliclazide; Glimepiride; Glucophage; Insulin; Insulin largine; Inulin; Linagliptin; Liraglutide; Lobeglitazone; Losartan; Metformin; Pioglitazone; Semaglutide; Sitagliptin; Thioctic acid; Troglitazone; Vildagliptin |
| Mechanism: | NAFLD progression is closely associated with insulin resistance and T2DM. Available evidence also suggests that a bidirectional relationship exists between NAFLD (or NASH) and T2DM. Both T2DM and obesity have been independently associated with an increased risk of developing NAFLD, and improvements in insulin sensitivity have been positively associated with histological improvements in NASH and fibrosis regression. |
| Reference (PMIDs): | 32061595 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D001 | Acarbose | Chemical drug | DB00284 | MGAM inhibitor;AMY2A inhibitor; AMY2B inhibitor; GAA inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D008 | Alpha-tocopherol | Chemical drug | DB00163 | NR1I2; ALOX5; DGKA | -- | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D033 | Bezafibrate | Chemical drug | DB01393 | PPARA agonist; PPARD agonist; PPARG agonist; NR1I2 partial agonist | Improve insulin resistance; Anti-inflammatory | Under clinical trials | Details |
| D038 | Biguanide | Chemical drug | DB13100 | -- | -- | Under clinical trials | Details |
| D058 | Canagliflozin | Chemical drug | DB08907 | SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D101 | Dapagliflozin | Chemical drug | DB06292 | SLC5A2 antagonist; SLC5A2 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D107 | Diacerein | Chemical drug | DB11994 | ALOX5 inhibitor | Antiarthritic drug; antiinflammatory agent | Under clinical trials | Details |
| D108 | Diamel | Chemical drug | DB00672 | -- | -- | Under clinical trials | Details |
| D113 | Dihydromyricetin | Chemical drug | DB15645 | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0015 | DB00046 | approved | biotech | Insulin lispro | Indication associated | Details |
| R0021 | DB00071 | approved | biotech | Insulin pork | Indication associated | Details |
| R0065 | DB00178 | approved | small molecule | Ramipril | Therapeutic strategy associated | Details |
| R0088 | DB00227 | approved; investigational | small molecule | Lovastatin | Therapeutic strategy associated | Details |
| R0144 | DB00414 | approved; investigational; withdrawn | small molecule | Acetohexamide | Indication associated | Details |
| R0168 | DB00489 | approved | small molecule | Sotalol | Indication associated | Details |
| R0169 | DB00491 | approved | small molecule | Miglitol | Indication associated | Details |
| R0170 | DB00492 | approved | small molecule | Fosinopril | Indication associated | Details |
| R0175 | DB00519 | approved | small molecule | Trandolapril | Indication associated | Details |
| R0227 | DB00641 | approved | small molecule | Simvastatin | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | Details |
| A00027 | 35250889 | Front Endocrinol (Lausanne) | Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | Details |
| A00036 | 35249342 | Ann Palliat Med | Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus. | Details |
| A00069 | 35232986 | Sci Rep | Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. | Details |
| A00074 | 35230042 | Swiss Med Wkly | Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. | Details |
| A00080 | 35227957 | Clin Res Hepatol Gastroenterol | The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. | Details |
| A00089 | 35223701 | Front Pediatr | Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. | Details |
| A00118 | 35215504 | Nutrients | Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. | Details |
| A00126 | 35212997 | Methods Mol Biol | Metabolic Phenotyping in Mice with NASH Using Indirect Calorimetry. | Details |
| A00147 | 35208513 | Medicina (Kaunas) | Evaluation of Dose-Dependent Obesity and Diabetes-Related Complications of Water Chestnut (Fruit of Trapa japonica) Extracts in Type II Obese Diabetic Mice Induced by 45% Kcal High-Fat Diet. | Details |
| A00158 | 35204522 | Diagnostics (Basel) | A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. | Details |
| A00164 | 35203659 | Biomedicines | Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. | Details |
| A00182 | 35195697 | JAMA Netw Open | Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | Details |
| A00187 | 35193889 | BMJ Open Gastroenterol | Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages-prospective study in Rajarata Pregnancy Cohort (RaPCo). | Details |
| A00188 | 35192934 | Mol Ther | Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. | Details |
| A00225 | 35176709 | Biomed Pharmacother | Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. | Details |
| A00232 | 35173677 | Front Endocrinol (Lausanne) | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement. | Details |
| A00238 | 35171411 | Med Biol Eng Comput | Exploring diet associations with Covid-19 and other diseases: a Network Analysis-based approach. | Details |
| A00241 | 35170435 | Saudi J Gastroenterol | Correlation between serum total bile acid and nonalcoholic fatty liver disease: A cross-sectional study. | Details |